Technical Analysis for LGND - Ligand Pharm

Grade Last Price % Change Price Change
grade B 113.0 14.20% 14.0500
LGND closed up 14.2 percent on Friday, November 29, 2019, on 55 percent of normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A
See historical LGND trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
New 52 Week High Strength 0.00%
Gapped Up Strength 0.00%
New 52 Week Closing High Bullish 14.20%
New 52 Week High Strength 14.20%
Multiple of Ten Bearish Other 14.20%
Gapped Up Strength 14.20%
New 52 Week Closing Low Bearish 31.01%
New 52 Week Low Weakness 31.01%
Gapped Down Weakness 31.01%
Older signals for LGND ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of seizure, coma, cancer, diabetes, cardiovascular diseases, muscle wasting, liver and kidney diseases, and others. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
RTT Cancer Biopharmaceutical Pharmaceutical Industry Drugs Pharmaceutical Diabetes Chemical Compounds Organic Compounds Autoimmune Diseases Breast Cancer Non Small Cell Lung Cancer Multiple Myeloma Cardiovascular Diseases Diabetes Mellitus Skin And Skin Structure Infections Medroxyprogesterone Acetate Delafloxacin Postmenopausal Osteoporosis

Is LGND a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 114.42
52 Week Low 86.1
Average Volume 213,195
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.0000
Average True Range 0.0000
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.0000
MACD Signal Line 0.0000
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 115.4000
Resistance 3 (R3) 115.6067 115.0133 115.0000
Resistance 2 (R2) 115.0133 114.4021 114.9100 114.8666
Resistance 1 (R1) 114.0067 114.0245 113.7100 113.8000 114.7333
Pivot Point 113.4133 113.4133 113.2650 113.3100 113.4133
Support 1 (S1) 112.4067 112.8021 112.1100 112.2000 111.2667
Support 2 (S2) 111.8133 112.4245 111.7100 111.1334
Support 3 (S3) 110.8067 111.8133 111.0000
Support 4 (S4) 110.6000